The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
Open accessAbstract
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with increased risk of Parkinson’s disease (PD). Thus, LRRK2 kinase inhibitors are in development as potential Parkinson’s disease therapeutics. A reduction in the constitutive levels of phosphorylation on leucine-rich repeat kinase 2 (LRRK2) is currently used to measure target engagement of LRRK2 kinase inhibitors in cell and animal models. We aimed to determine if reduced phosphorylation of LRRK2 following inhibitor treatment is also a valid measure of target engagement in peripheral mononuclear cells from Parkinson’s disease patients. Peripheral mononuclear cells from idiopathic Parkinson’s disease patients and controls were treated ex vivo with two structurally distinct inhibitors of LRRK2, at four different doses and immunoblotting was used to assess the reduction in LRRK2 phosphorylation at Ser910, Ser935, Ser955 and Ser973. Both inhibitors showed no acute toxicity in primary cells and both inhibitors reduced the constitutive phosphorylation of LRRK2 at all measured residues equally in both control and Parkinson’s disease groups. Measuring the reduction in LRRK2 phosphorylation resulting from LRRK2 kinase inhibition, is thus a valid measure of acute peripheral target engagement in Parkinson’s disease patients. This is important if LRRK2 kinase inhibitors are to be used in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Cited by
LRRK2 levels in immune cells are increased in Parkinson’s disease
Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., Grigoryan, N., Factor, S. A., West, A. B., Boss, J. M., et al. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0010-8 · Cited by 279
Tosi, S., Costa, C., Vesco, U., Quaglia, G., & Guido, G. (2018) · Science of The Total Environment · doi:10.1016/j.scitotenv.2017.09.226 · Cited by 267
Raabe, D., Sun, B., Kwiatkowski Da Silva, A., Gault, B., Yen, H.-W., Sedighiani, K., Thoudden Sukumar, P., Souza Filho, I. R., Katnagallu, S., Jägle, E., et al. (2020) · Metallurgical and Materials Transactions A · doi:10.1007/s11661-020-05947-2 · Cited by 257
LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients
Atashrazm, F., Hammond, D., Perera, G., Bolliger, M. F., Matar, E., Halliday, G. M., Schüle, B., Lewis, S. J. G., Nichols, R. J., & Dzamko, N. (2019) · Movement Disorders · doi:10.1002/mds.27601 · Cited by 102
Self-citationThe PTSD Systems Biology Consortium, Dean, K. R., Hammamieh, R., Mellon, S. H., Abu-Amara, D., Flory, J. D., Guffanti, G., Wang, K., Daigle, B. J., Gautam, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0496-z · Cited by 101
Fernández, B., Lara Ordóñez, A. J., Fdez, E., Mutez, E., Comptdaer, T., Leghay, C., Kreisler, A., Simonin, C., Vandewynckel, L., Defebvre, L., et al. (2019) · Biochemical Journal · doi:10.1042/bcj20190315 · Cited by 33
Nash, M. C., Adey, W., & Harvey, A. S. (2021) · Journal of Phycology · doi:10.1111/jpy.13098 · Cited by 7
Metadata
- Authors
- Perera, G., Ranola, M., Rowe, D. B., Halliday, G. M., & Dzamko, N.
- Venue
- Scientific Reports
- Published
- 2016-08-09
- Volume
- 6
- Issue
- 1
- Pages
- 31391-31391
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2520855151
- Cited by
- 259
- References
- 1
- FWCI
- 15.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.